Author: admin

Dr. Peter A. McCullough selected for the Lifetime Achievement Award for 2024 by IAOTP

Dr. Peter A. McCullough selected for the Lifetime Achievement Award for 2024 by IAOTP

Dr. Peter A. McCullough, world renown physician, media commentator, author, and public figure, was recently selected for the prestigious Lifetime Achievement Award for 2024 by the International Association of Top Professionals (IAOTP) for his outstanding leadership, dedication, and commitment to the industry.

Inclusion with the International Association of Top Professionals is an honor in itself; only a few members in each discipline are chosen for this distinction.  These special honorees are distinguished based on their professional accomplishments, academic achievements, leadership abilities, longevity in the field, other affiliations, and contributions to their communities. All Honorees are invited to attend the IAOTP annual award gala at the end of this year for a night to honor their achievements.

www.iaotp.com/award-gala

With over 3 decades of experience, Dr. McCullough is a pillar in academic medicine.  He is a practicing internist, cardiologist, and epidemiologist in Dallas, Texas, and the Chief Scientific Officer of the Wellness Company.

Dr. McCullough has written extensively on a wide variety of medical issues, having over 1000 articles and over 680 citations in the National Library of Medicine. He has served as editor-in-chief and on the editorial boards of many subspeciality journals. He has led data safety monitoring boards of 24 randomized clinical studies.

Before embarking on his professional career path, Dr. McCullough earned his Bachelor’s degree at Baylor University and his Medical degree as an Alpha Omega Alpha graduate of the University of Texas Southwestern Medical School. He then went on to do his internal medicine residency at the University of Washington, Cardiology fellowship at William Beaumont Hospital, and completed a Master’s degree in public health at the University of Michigan.

Throughout his illustrious career, Dr. McCullough has received many awards and accolades and has been recognized worldwide for his accomplishments. In 2023, Dr. McCullough was featured on the Nasdaq Billboard in Times Square, and he was awarded Top Internist and Cardiologist of the Year by IAOTP. This year he is being considered for a feature in TIP (Top Industry Professionals) Magazine. He will be honored at IAOTP’s annual awards gala at the Gaylord Opryland Resort in Nashville this December for his selection of Lifetime Achievement Award for 2024. 

In addition to his successful career Dr. McCullough has been a leader in the medical response to the COVID-19 disaster since the beginning of the pandemic, publishing “Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection,” as the McCullough Protocol for ambulatory high-risk COVID-19 in the American Journal of Medicine and Reviews in Cardiovascular Medicine.  His breakthrough McCullough Protocol Base Spike Detoxification for post-acute sequelae after SARS-CoV-2 infection and vaccination was published in Journal of American Physicians and Surgeons and CUREUS.   He has dozens of peer-reviewed articles on the virus and has contributed significantly to The Hill, FOX NEWS Channel, NEWSMAX, OAN, ABC News, and America Out Loud Talk Radio on the medical response to the COVID-19 problem. Dr. McCullough testified on many aspects of the pandemic response before the US Senate Committee on Homeland Security and Governmental Affairs and Special Panels, US House of Representatives, the Texas Senate Committee on Health and Human Services, the Colorado General Assembly, Arizona Senate, New Hampshire Senate, South Carolina Senate, and the Pennsylvania Senate.

The President of the International Association of Top Professionals (IAOTP), Stephanie Cirami, stated: “Choosing Dr. McCullough for this honor was an easy decision for our panel to make. He is inspirational, influential, and a true visionary and thought leader. We cannot wait to see him and celebrate his accomplishments at this year’s gala.”

Looking back, Dr. McCullough attributes his success to his perseverance, work ethic, and the mentors he has had along the way. When not working, he enjoys traveling and spending time with his family. In the future, he hopes to inspire and influence those getting into the field.

For more information please visit:

https://www.linkedin.com/in/petermcculloughmd/

https://www.petermcculloughmd.com/

https://couragetofacecovid.com/

https://petermcculloughmd.substack.com/

https://www.twc.health/

About IAOTP

The International Association of Top Professionals (IAOTP) is an international boutique networking organization that handpicks the world’s finest, most prestigious top professionals from different industries.  These top professionals are given an opportunity to collaborate, share their ideas, be keynote speakers, and to help influence others in their fields. This organization is not a membership that anyone can join.  You have to be asked by the President or be nominated by a distinguished honorary member after a brief interview.

IAOTP’s experts have given thousands of top prestigious professionals around the world the recognition and credibility that they deserve and have helped in building their branding empires.  IAOTP prides itself to be a one-of-a-kind boutique networking organization that hand picks only the best of the best and creates a networking platform that connects and brings these top professionals to one place.

For More information on IAOTP please visit: www.iaotp.com

Media Contact
Company Name: IAOTP
Contact Person: Media Relations
Email: Send Email
Phone: (212) 634-4427
Country: United States
Website: https://iaotp.com

Enhancing Financial Vigilance: A Comprehensive Guide to Avoiding Investment Scams with Eternity Inc

In an era where financial scams are increasingly sophisticated, safeguarding one’s financial well-being has never been more critical. Eternity Inc plays a pivotal role in empowering individuals with the knowledge and tools to navigate the perilous waters of investment fraud. This guide not only outlines practical steps for protecting oneself but also delves into various types of scams to watch out for, ensuring a well-rounded defense strategy.

Verifying Credentials and Investment Registrations

A fundamental step in due diligence is to verify the credentials of the person or entity offering the investment. It’s crucial to ensure that the sellers are properly licensed, which is a basic requirement for legitimacy. Similarly, investments themselves often need to be registered with the relevant financial regulatory authorities, providing an additional layer of security for potential investors.

Recognizing Common Investment Scams

Awareness of the landscape of financial fraud is crucial for prevention. Here are several prevalent scams:

  • Ponzi Schemes: Investors are promised high returns, paid from the investments of new investors rather than genuine profits.
  • Pyramid Schemes: Similar to Ponzi schemes but based on recruiting more investors to sustain returns.
  • Advance Fee Frauds: Victims are persuaded to pay upfront fees to secure investments that never materialize.
  • Pump and Dump Scams: Fraudsters inflate the price of owned stocks through misleading statements, then sell off the stocks at a high price before the truth emerges, causing the value to plummet.
  • Binary Options Scams: Offering high returns on investments by predicting the movement of assets, these often operate without regulation, leading to significant losses.

Essential Defensive Practices

  • Beware of Unrealistic Promises: High returns with low risk are a hallmark of fraudulent offers.
  • Avoid High-Pressure Sales: Legitimate investments never require immediate action.
  • Treat Unsolicited Offers with Skepticism: Especially those via phone or online platforms.
  • Demand Documentation: Always ask for a prospectus or offering circular before investing.
  • Consult Neutral Third Parties: Discuss potential investments with a trusted financial advisor or consultant.

Enhancing Security with Eternity Inc’s Community Approach

Eternity Inc bolsters individual defenses against scams through community education and shared experiences. This collaborative approach includes:

  • Educational Workshops and Webinars: Tailored to equip members with the knowledge to spot and avoid scams.
  • Experience Sharing: A forum for members to share their encounters with scams, fostering a collective pool of knowledge.
  • Expert Consultations: Access to financial experts for advice on fraud prevention and financial planning.

Proactive Financial Habits for Comprehensive Protection

Incorporating vigilant financial habits is indispensable for a robust defense against scams. This includes regularly monitoring financial accounts, using secure communication channels, organizing financial documents clearly, and staying informed about scamming tactics.

Navigating the Digital Threat Landscape

The digital age has made online scams particularly prevalent. It’s imperative to approach online investment opportunities with a high degree of caution, conducting thorough research and verifying the legitimacy of any investment offer encountered on social media or the internet.

Conclusion

Securing one’s financial future against scams requires a multifaceted strategy, combining personal vigilance, informed decision-making, and the power of community support. Eternity Inc’s commitment to financial education and its proactive community platform provide a solid foundation for individuals to enhance their defenses against the spectrum of investment scams. By embracing these strategies and participating in knowledgeable communities, individuals can significantly bolster their protection, ensuring a safer financial journey amidst the evolving threats of investment fraud.

Media Contact
Company Name: Eternity Prime Limited
Contact Person: Roman Leithaeuser
Email: Send Email
Phone: +436609658246
Address:Donau-City-Strasse 3
City: Vienna
Country: Austria
Website: https://eternity.inc/

DERMARSSANCE, a specialized beauty brand that encapsulates dermatologists’ prescriptions in dermacosmetics (dermatology + cosmetics), focuses exclusively on collagen

DERMARSSANCE was born with a clear focus on efficacy and unwavering values to deliver better skin. It addresses skin that has been exposed to harmful environments and stress, providing scientific solutions for radiant skin and boosting self-confidence.

Since 2018, DERMARSSANCE has been exported to over 40 countries worldwide through global partnerships. The expert research team has developed precise and professional solutions to address the root of skin concerns. Collaborating with the medical company H&S BIOLAB, we have optimized ingredients to create a unique formula that caters to skin’s specific needs.

The HIGHPRIME COLLAGEN FILM is a specialized skincare product with unique features

It contains Type 1 collagen, which closely resembles the collagen found in the skin’s dermal layer. This collagen component helps prevent skin aging and promotes elasticity by aiding collagen formation. It has been clinically tested for human application at a specialized skin clinical institution. 

Derived from SANFORD, a reputable company with a 130-year tradition from the pristine South Pacific region of New Zealand, the collagen film mimics the structure of the skin’s dermal layer. This Type I collagen component helps prevent skin from aging and promotes elasticity by aiding collagen formation.

The thin and lightweight collagen product, which applies patented porous nano-piper technology in the Dermalayer, dissolves instantly upon contact with the skin due to its innovative electrospinning technique and rapidly penetrates the skin.

The preservative-free special care film is 100% comprised of only collagen and hyaluronic acid which are concentrated and dried into a nano-fiber film using patented technology to provide stable and rapid effects to skin .

You can target specific facial areas such as the forehead, neck, cheeks, and eye regions for focused care.

The 3 Types of Ultra Collagen is the optimal solution for noticeable deep wrinkles and aged skin.

Its rich and luxurious texture imparts smoothness and flexibility, providing elasticity to the skin. The ultra-low molecular weight collagen ensures thorough absorption, making it an ideal choice for skin rejuvenation.

If you desire a richer nutritional experience, you can create a cream-smoothing effect with DERMARSSANCE’s 3 Types of Ultra Collagen. Simply pump the cream and use the inside of the container like a palette to mix in the serum. This hygienic method ensures both safety and a luminous skincare routine. 

DERMARSSANCE+ is DERMARSSANCE for Professional use.

Healthy skin begins with youthful cells within the skin.

It is a cosmeceutical brand that harnesses scientific data obtained from dermatological research to restore the inherent strength of skin cells and produce cell-renewal factors, achieving anti-aging effects on the skin.

The entire process, from skin research to manufacturing, has been collaboratively developed by a team of medical experts, including Professor Kim Hyung-Sik, a pharmacist from Sungkyunkwan University.

Verified solutions incorporated with the concept of medical treatment using medical-grade ingredients / Uniform and stable nano-molecule skin penetration technology / Unique high-concentration blending techniques for fundamental skin care.

OXYGEN CORE INFUSER PROGRAM

The O2 Layering Care Oxygen Core Infuser Program that you received from a skin specialist provides

High-concentration oxygen provides vitality to skin cells and accelerates cellular metabolism, aiding in the rapid regeneration of damaged cells

Skin regeneration through fresh oxygen supply!

By supplying sufficient oxygen to the skin layers, it aids in cell regeneration and prevents aging. The unique absorption rate of nano particles! The fine nano particles are directly absorbed by the skin without lingering on the surface, providing immediate nourishment

Home aesthetic care, just like the professional treatments you received at specialized skin clinics.

With the compact-sized Oxygen Core Infuser designed ergonomically, you can now enjoy home aesthetic care that is just the professional treatments you received for skin management.

Media Contact
Company Name: DERMARSSANCE
Contact Person: Angelokim
Email: Send Email
Country: Korea
Website: https://www.dermarssance.com/

Nano-Cap Stocks On The Move Watchlist (ORHB, NHMD, SFRX)

In the stock market, small-cap stocks are frequently hotbeds of innovation and groundbreaking ideas. These companies, typically characterized by their modest market capitalization, embody the entrepreneurial spirit and drive for growth that define the essence of the market.

Exploring the world of nanocap stocks reveals a wealth of potential and market impact worthy of examination. Let’s check out a few notable examples, all priced under $.05.

HippoFi (OTC: ORHB)

HippoFi is a driving force in the healthcare industry, powered by cutting-edge technologies and a novel approach to medicine. The company’s dedication to delivering innovative healthcare solutions is unmistakable through its focused efforts on pioneering first-to-market solutions across the multibillion-dollar biotech, fintech, and AI sectors.

At the core of HippoFi’s success lie its proprietary technologies, meticulously crafted to address critical medical needs and enhance patient outcomes. Anchoring its operations is PUR Biologics, the company’s regenerative therapeutics division, committed to developing and deploying scalable biological solutions within the $1.37 trillion biotechnology market.

HippoFi’s portfolio of technologies includes advanced allografts and demineralized extracellular matrices (d-ECM), representing groundbreaking advancements in tissue regeneration and repair. These innovative solutions offer a comprehensive approach to healing, aiming to restore function and mobility to patients suffering from degenerative conditions.

Moreover, HippoFi’s synthetic bone-forming solutions and cellular-derived tissues signify significant milestones in orthopedic care. By harnessing the power of regenerative stem cells and growth factors, HippoFi is pioneering next-generation therapeutics for treating osteoarthritis and facilitating cartilage regeneration.

What sets HippoFi apart is its commitment to personalized medicine, leveraging biotech and AI technologies to develop tailored treatments for individual patient needs. Through strategic partnerships with industry leaders such as ZIMMER BIOMET and Hoag Hospital Newport Beach, HippoFi is driving innovation in spine care solutions, revolutionizing the delivery of spinal biologics.

The recent acquisition of activeOrb technology further solidifies HippoFi’s position as a leader in the regenerative therapeutics market. This cutting-edge technology enhances HippoFi’s capabilities in bone-growth solutions, reaffirming its commitment to advancing healthcare technologies and solutions.

HippoFi’s exponential growth is evident in its expanding distribution network and international market penetration. With expectations of sales exceeding $20 million in the coming year, HippoFi is poised for substantial revenue growth and market expansion.

In summary, HippoFi’s proprietary technologies, strategic partnerships, and exponential growth trajectory position it as a trailblazer in the healthcare sector. By harnessing the power of biotech and AI, HippoFi is spearheading transformative treatments that have the potential to revolutionize patient care and drive significant value for shareholders.

Nate’s Food Co. (OTC: NHMD) 

Nate’s Food Co. is a dynamic and forward-thinking company dedicated to providing high-quality solutions to its clients, with a strong focus on the commodity business.

Last year, the company proudly announced the attainment of official registration from the General Administration of Customs of the People’s Republic of China (GACC). This achievement marks a pivotal moment for the company, clearing the path for the execution of contracts for a diverse range of commodities in the Chinese market. The GACC registration underscores Nate’s Food Co.’s unwavering dedication to adherence to compliance, quality, and the strategic pursuit of global market expansion.

More recently, Nate’s Food Co. is thrilled to announce a groundbreaking joint venture agreement for the sale of $8 billion in aviation fuel. This collaboration involves a direct partnership with a highly regarded refinery allotment holder, ensuring a reliable monthly allotment of up to 8 million barrels of aviation fuel. The company’s CEO expressed enthusiasm for this pivotal partnership, stating that it represents a remarkable achievement for the company as it solidifies its position in the aviation fuel market.

Further solidifying its presence in the commodities market, Nate’s Food Co. successfully secured a purchase order for 49,000,000 barrels of jet fuel, valued at nearly $5 billion based on current Platts pricing. This achievement highlights the company’s ability to secure significant contracts and capitalize on emerging opportunities in the commodities market.

Nate’s Food Co.’s strategic focus includes obtaining its fuel storage tanks in Rotterdam, Netherlands, and Houston, Texas, further enhancing its capabilities in fuel distribution and market penetration.

With these recent achievements and strategic initiatives, Nate’s Food Co. is poised for continued growth and success in the global commodities industry.

Seafarer Exploration Corp. (OTC: SFRX) 

SFRX is a publicly traded company focused on underwater exploration and technology, particularly in the archaeologically sensitive research, documentation, exploration, recovery, and conservation of historic shipwrecks. The company has secured multiple sites believed to contain valuable shipwrecks and employs scientists and historians to preserve the cultural and historical significance of each discovery.

Recently, Seafarer announced significant developments regarding its Juno Beach project in Juno Beach, Florida. The company obtained a 5-year Letter of Permission from the United States Army Corps of Engineers (USACE), allowing it to engage in research and exploration activities. Seafarer also secured an Admiralty in Rem claim by the United States District Court, granting exclusive ownership of an unidentified shipwreck at Juno Beach. Furthermore, the company received permits from the Florida Department of Environmental Protection (FDEP) and a Sovereign Submerged Lands Cultural Resource Recovery Easement for the site, providing sole rights to commence operations at Juno Beach.

The issuance of the USACE permit marks a significant milestone for Seafarer, allowing it to fully investigate the mysteries surrounding the mid-1500s shipwreck at Juno Beach. The company is equipped with seasoned underwater archaeologists, advanced technology, and specialized equipment to handle the unique challenges presented by the site.

Seafarer’s progress in 2023 includes the successful recovery of a silver coin from the Juno Beach site, dating back to the mid-16th century. The company has also strengthened its team’s expertise and secured million-dollar debt financing to support its exploratory and operational activities.

With all necessary permits secured and promising non-ferrous targets identified using proprietary technology, Seafarer is poised for an exciting year ahead. The company’s financing position, operational readiness, and media partnerships position it for success in its upcoming endeavors.

Investors have responded positively to these developments, with the stock rising by 8.44% on February 6th, reflecting growing confidence in Seafarer’s capabilities and future prospects.

 

Disclaimers:CapitalGainsReport (CGR) is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance that are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. CapitalGainsReport (CGR) is owned by RazorPitch Inc. and has been retained by HippoFi Inc. to assist in the production and distribution of content related to ORHB. ‘CGR’  is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by CapitalGainsReport/RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. CGR/RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.

Media Contact
Company Name: Capital Gains Report
Contact Person: Mark McKelvie
Email: Send Email
City: NAPLES
State: FLORIDA
Country: United States
Website: https://capitalgainsreport.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Nano-Cap Stocks On The Move Watchlist (ORHB, NHMD, SFRX)

Minimal Residual Disease Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Adaptive Biotechnologies, Foresight Diagnostics, Cergentis B.V., ICON plc

Minimal Residual Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Minimal Residual Disease, historical and forecasted epidemiology as well as the Minimal Residual Disease market trends in the 7MM.

DelveInsight’s “Minimal Residual Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Minimal Residual Disease, historical and forecasted epidemiology as well as the Minimal Residual Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Minimal Residual Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Minimal Residual Disease Market Forecast

 

Some of the key facts of the Minimal Residual Disease Market Report: 

  • The Minimal Residual Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In the United States, there are around 6,000 individuals with ALL, with half of them being children and the other half adults, according to the study by Jabbour and Park (2022)
  • The overall number of minimal residual disease testing cases in the 7MM for the year 2021 was determined to be 1,219,739 cases. The US and Germany were the two countries with the highest number of MRD testing cases
  • A significant number of adult ALL patients experience relapse despite reaching complete remission (CR), with a reported relapse incidence of 40–50%, according to CatALLyst (2021). Additionally, 30–40% of patients who achieve CR test positive for MRD, suggesting that they may still have some cancer cells in their bone marrow
  • In the 7MM, there were 98,720, 368,298, 339,478, 149,497, 15,992, and 247,754 MRD tests performed on blood malignancies in the year 2021, for ALL, CLL, AML, CML, MM, and Lymphoma, respectively
  • Key Minimal Residual Disease Companies: Adaptive Biotechnologies, Foresight Diagnostics, Cergentis B.V., ICON plc, 3B BlacBio Biotech, EntroGen, Quest Diagnostics, ImmuQuad, Foresight Diagnostics, Cergentis B.V., Natera, Invivoscribe Inc., Idylla Technology, and others
  • Key Minimal Residual Disease Therapies: ClonoSEQ, PhasED-Seq, Targeted Locus Amplification (TLA) technology, MRDx BCR-ABL Test, TRUPCR® PML-RARA, Leukemia Fusion Gene One-Step Detection Kits, CBFB/MYH11 inv(16), Seq-MRD, ClonoSEQ, PhasED-Seq, Targeted Locus Amplification (TLA) technology, MRDx BCR-ABL Test, Signatera, LymphoTrack, Biocartis, and others
  • The Minimal Residual Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Minimal Residual Disease pipeline products will significantly revolutionize the Minimal Residual Disease market dynamics.

 

Minimal Residual Disease Overview

Small quantities of cancer cells that remain in the body after treatment are known as minimal residual disease (MRD). These cells have the capacity to recur and trigger relapses. For instance, in leukaemia, doctors examine bone marrow samples under a microscope for cancer cells to see if the disease has responded to treatments.

 

Get a Free sample for the Minimal Residual Disease Market Report 

https://www.delveinsight.com/report-store/minimal-residual-disease-market

 

Minimal Residual Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Minimal Residual Disease Epidemiology Segmentation:

The Minimal Residual Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Minimal Residual Disease
  • Prevalent Cases of Minimal Residual Disease by severity
  • Gender-specific Prevalence of Minimal Residual Disease
  • Diagnosed Cases of Episodic and Chronic Minimal Residual Disease

 

Download the report to understand which factors are driving Minimal Residual Disease epidemiology trends @ Minimal Residual Disease Epidemiology Forecast

 

Minimal Residual Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Minimal Residual Disease market or expected to get launched during the study period. The analysis covers Minimal Residual Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Minimal Residual Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Minimal Residual Disease Therapies and Key Companies

  • ClonoSEQ: Adaptive Biotechnologies
  • PhasED-Seq: Foresight Diagnostics
  • Targeted Locus Amplification (TLA) technology: Cergentis B.V.
  • MRDx BCR-ABL Test: ICON plc
  • TRUPCR® PML-RARA: 3B BlacBio Biotech
  • Signatera: Natera
  • Leukemia Fusion Gene One-Step Detection Kits: EntroGen
  • CBFB/MYH11 inv(16): Quest Diagnostics
  • Seq-MRD: ImmuQuad
  • PhasED-Seq: Foresight Diagnostics
  • Targeted Locus Amplification (TLA) technology: Cergentis B.V.
  • TRUPCR® PML-RARA: 3B BlacBio Biotech
  • CBFB/MYH11 inv(16): Quest Diagnostics
  • LymphoTrack: Invivoscribe Inc.Biocartis: Idylla Technology

 

Discover more about therapies set to grab major Minimal Residual Disease market share @ Minimal Residual Disease Treatment Market 

 

Minimal Residual Disease Market Strengths

  • Several organizations and companies like the European Scientific foundation for Laboratory Hemato Oncology (ESLHO), Leukemia and Lymphoma Society (LLS) and European LeukemiaNet (ELN), among many more, are raising awareness about the disease, which can lead to the increased patient pool.
  • The recent advances in high-throughput technologies in molecular genetics may now provide a novel approach to detect MRD like next-generation sequencing (NGS).

 

Minimal Residual Disease Market Opportunities

  • Increased use of MRD testing can create new opportunities by identifying the patients who could benefit from consolidative HDT-ASCT and/or prolonged therapy.
  • The development of more accurate diagnostic methods with high sensitivity can detect even the smallest amount of MRD cells.

 

Scope of the Minimal Residual Disease Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Minimal Residual Disease Companies: Adaptive Biotechnologies, Foresight Diagnostics, Cergentis B.V., ICON plc, 3B BlacBio Biotech, EntroGen, Quest Diagnostics, ImmuQuad, Foresight Diagnostics, Cergentis B.V., Natera, Invivoscribe Inc., Idylla Technology, and others
  • Key Minimal Residual Disease Therapies: ClonoSEQ, PhasED-Seq, Targeted Locus Amplification (TLA) technology, MRDx BCR-ABL Test, TRUPCR® PML-RARA, Leukemia Fusion Gene One-Step Detection Kits, CBFB/MYH11 inv(16), Seq-MRD, ClonoSEQ, PhasED-Seq, Targeted Locus Amplification (TLA) technology, MRDx BCR-ABL Test, Signatera, LymphoTrack, Biocartis, and others
  • Minimal Residual Disease Therapeutic Assessment: Minimal Residual Disease current marketed and Minimal Residual Disease emerging therapies
  • Minimal Residual Disease Market Dynamics: Minimal Residual Disease market drivers and Minimal Residual Disease market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Minimal Residual Disease Unmet Needs, KOL’s views, Analyst’s views, Minimal Residual Disease Market Access and Reimbursement 

 

To know more about Minimal Residual Disease companies working in the treatment market, visit @ Minimal Residual Disease Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Minimal Residual Disease Market Report Introduction

2. Executive Summary for Minimal Residual Disease

3. SWOT analysis of Minimal Residual Disease

4. Minimal Residual Disease Patient Share (%) Overview at a Glance

5. Minimal Residual Disease Market Overview at a Glance

6. Minimal Residual Disease Disease Background and Overview

7. Minimal Residual Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Minimal Residual Disease 

9. Minimal Residual Disease Current Treatment and Medical Practices

10. Minimal Residual Disease Unmet Needs

11. Minimal Residual Disease Emerging Therapies

12. Minimal Residual Disease Market Outlook

13. Country-Wise Minimal Residual Disease Market Analysis (2019–2032)

14. Minimal Residual Disease Market Access and Reimbursement of Therapies

15. Minimal Residual Disease Market Drivers

16. Minimal Residual Disease Market Barriers

17.  Minimal Residual Disease Appendix

18. Minimal Residual Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Minimal Residual Disease Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Adaptive Biotechnologies, Foresight Diagnostics, Cergentis B.V., ICON plc

Migraine Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies involved by DelveInsight | GlaxoSmithKline, Merck & Co., Inc., Pfizer, Bausch Health, Amgen, Abbvie

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Migraine pipeline constitutes 30+ key companies continuously working towards developing 30+ Migraine treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Migraine Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Migraine Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Migraine Market.

 

Some of the key takeaways from the Migraine Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Migraine treatment therapies with a considerable amount of success over the years. 
  • Migraine companies working in the treatment market are Eli Lilly and Company, Satsuma Pharmaceuticals, Pulmatrix, Vaxxinity, Inc., Tonix Pharmaceuticals, Inc, AEON Biopharma, Inc., Axsome Therapeutics, Pfizer, and others, are developing therapies for the Migraine treatment 
  • Emerging Migraine therapies in the different phases of clinical trials are- LY3451838, STS-101, PUR-3100, UB-313, TNX-1900, ABP-450, AXS 07, Zavegepant, and others are expected to have a significant impact on the Migraine market in the coming years.   
  • In December 2023, Teva Pharmaceuticals has revealed encouraging findings from a retrospective examination of the Phase III HALO-LTS and FOCUS clinical studies, evaluating the effects of Ajovy (fremanezumab) in individuals experiencing migraines alongside obesity-related conditions.
  • In August 2022, Axsome Therapeutics, Inc. has commenced a study called “A Trial Without Restrictions, Assessing Multiple Doses to Determine How Effective and Safe AXS-07 (Meloxicam and Rizatriptan) Is for Treating Sudden Onset of Migraines in Adults Previously Unresponsive to Oral CGRP Inhibitors.
  • In May 2022, Axsome Therapeutics, Inc. disclosed that it has obtained a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) concerning its New Drug Application (NDA) for AXS-07 intended for the immediate treatment of migraines.
  • In February 2022, Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has provided a favorable recommendation for Rimegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist. The CHMP suggests the approval of the 75 mg dose of orally dissolving Rimegepant tablets for marketing authorization. This approval extends to both the immediate treatment of migraines with or without aura in adults and the preventive treatment of episodic migraines in adults facing at least four migraine attacks per month.
  • In January 2022, BioDelivery Sciences has introduced a new medication named Elyxyb (celecoxib oral solution), a swiftly effective liquid formulation. This product stands among the initial Food and Drug Administration-approved ready-to-administer oral solutions designed for adults in promptly addressing migraines, whether accompanied by aura or not.

 

Migraine Overview

Strong headaches are a common side effect of the neurological condition migraine. The headache occurs in spurts and occasionally coexists with light sensitivity, nausea, and vomiting. One of the main causes of impairment in the globe is migraine. About 15% of Americans suffer from migraines.

 

Get a Free Sample PDF Report to know more about Migraine Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/migraine-pipeline-insight

 

Emerging Migraine Drugs Under Different Phases of Clinical Development Include:

  • LY3451838: Eli Lilly and Company
  • STS-101: Satsuma Pharmaceuticals
  • PUR-3100: Pulmatrix
  • UB-313: Vaxxinity, Inc.
  • TNX-1900: Tonix Pharmaceuticals, Inc
  • ABP-450: AEON Biopharma, Inc.
  • AXS 07: Axsome Therapeutics
  • Zavegepant: Pfizer

 

Migraine Route of Administration

Migraine pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

 

Migraine Molecule Type

Migraine Products have been categorized under various Molecule types, such as

  • Oligonucleotide
  • Peptide
  • Small molecule

 

Migraine Pipeline Therapeutics Assessment

  • Migraine Assessment by Product Type
  • Migraine By Stage and Product Type
  • Migraine Assessment by Route of Administration
  • Migraine By Stage and Route of Administration
  • Migraine Assessment by Molecule Type
  • Migraine by Stage and Molecule Type

 

DelveInsight’s Migraine Report covers around 30+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Migraine product details are provided in the report. Download the Migraine pipeline report to learn more about the emerging Migraine therapies

 

Some of the key companies in the Migraine Therapeutics Market include:

Key companies developing therapies for Migraine are – GlaxoSmithKline, Merck & Co., Inc., Pfizer, Bausch Health, Amgen, Abbvie Inc., AstraZeneca, Eli Lilly and Co., Teva Pharmaceuticals, Novartis AG, Eisai Co., Ltd., Abbott Laboratories, and others.

 

Migraine Pipeline Analysis:

The Migraine pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Migraine with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Migraine Treatment.
  • Migraine key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Migraine Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Migraine market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Migraine drugs and therapies

 

Migraine Pipeline Market Drivers

  • Increasing prevalence of Migraine, significant progress is being made in the preventative treatment of chronic migraine, growing awareness regarding migraine are some of the important factors that are fueling the Migraine Market.

 

Migraine Pipeline Market Barriers

  • However, lack of proper diagnosis, various side-effects associated with the available drugs and other factors are creating obstacles in the Migraine Market growth.

 

Scope of Migraine Pipeline Drug Insight    

  • Coverage: Global
  • Key Migraine Companies: Eli Lilly and Company, Satsuma Pharmaceuticals, Pulmatrix, Vaxxinity, Inc., Tonix Pharmaceuticals, Inc, AEON Biopharma, Inc., Axsome Therapeutics, Pfizer, and others
  • Key Migraine Therapies: LY3451838, STS-101, PUR-3100, UB-313, TNX-1900, ABP-450, AXS 07, Zavegepant, and others
  • Migraine Therapeutic Assessment: Migraine current marketed and Migraine emerging therapies
  • Migraine Market Dynamics: Migraine market drivers and Migraine market barriers 

 

Request for Sample PDF Report for Migraine Pipeline Assessment and clinical trials

 

Table of Contents

1. Migraine Report Introduction

2. Migraine Executive Summary

3. Migraine Overview

4. Migraine- Analytical Perspective In-depth Commercial Assessment

5. Migraine Pipeline Therapeutics

6. Migraine Late Stage Products (Phase II/III)

7. Migraine Mid Stage Products (Phase II)

8. Migraine Early Stage Products (Phase I)

9. Migraine Preclinical Stage Products

10. Migraine Therapeutics Assessment

11. Migraine Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Migraine Key Companies

14. Migraine Key Products

15. Migraine Unmet Needs

16 . Migraine Market Drivers and Barriers

17. Migraine Future Perspectives and Conclusion

18. Migraine Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Migraine Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies involved by DelveInsight | GlaxoSmithKline, Merck & Co., Inc., Pfizer, Bausch Health, Amgen, Abbvie

Generalized Anxiety Disorder Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies involved by DelveInsight | OWP Pharmaceuticals, Mind Medicine, Inc, Luye Pharma

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Generalized Anxiety Disorder pipeline constitutes 10+ key companies continuously working towards developing 12+ Generalized Anxiety Disorder treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Generalized Anxiety Disorder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Generalized Anxiety Disorder Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Generalized Anxiety Disorder Market.

 

Some of the key takeaways from the Generalized Anxiety Disorder Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Generalized Anxiety Disorder treatment therapies with a considerable amount of success over the years. 
  • Generalized Anxiety Disorder companies working in the treatment market are  OWP Pharmaceuticals, Mind Medicine, Inc, Luye Pharma Group, ChemRar Research and Development Institute, LLC, and others, are developing therapies for the Generalized Anxiety Disorder treatment 
  • Emerging Generalized Anxiety Disorder therapies in the different phases of clinical trials are- Duloxetine oral suspension, MM-120, LY03005, CD-008-0045, and others are expected to have a significant impact on the Generalized Anxiety Disorder market in the coming years.   
  • MindMed, a prominent participant in the treatment of generalized anxiety disorder, has investigated the possible therapeutic advantages of 5-MeO-DMT, a psychedelic chemical that is naturally present in a variety of plants and animals. 5-MeO-DMT may have anxiolytic (anti-anxiety) effects, according to MindMed’s preclinical research, which could make it a helpful therapeutic choice for those with generalized anxiety disorder.

 

Generalized Anxiety Disorder Overview

People with generalized anxiety disorder (GAD) typically have a constant sense of dread or anxiety that interferes with their day-to-day activities. It is not the same as periodically feeling anxious or worried about things because of unpleasant situations in life. Anxiety is a common occurrence for people with GAD lasting months or even years at a time.

 

Get a Free Sample PDF Report to know more about Generalized Anxiety Disorder Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/generalized-anxiety-disorder-pipeline-insight

 

Emerging Generalized Anxiety Disorder Drugs Under Different Phases of Clinical Development Include:

  • Duloxetine oral suspension: OWP Pharmaceuticals
  • MM-120: Mind Medicine, Inc
  • LY03005: Luye Pharma Group
  • CD-008-0045: ChemRar Research and Development Institute, LLC

 

Generalized Anxiety Disorder Route of Administration

Generalized Anxiety Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Intravenous
  • Oral
  • Intramuscular

 

Generalized Anxiety Disorder Molecule Type

Generalized Anxiety Disorder Products have been categorized under various Molecule types, such as

  • Small molecules
  • Peptides

 

Generalized Anxiety Disorder Pipeline Therapeutics Assessment

  • Generalized Anxiety Disorder Assessment by Product Type
  • Generalized Anxiety Disorder By Stage and Product Type
  • Generalized Anxiety Disorder Assessment by Route of Administration
  • Generalized Anxiety Disorder By Stage and Route of Administration
  • Generalized Anxiety Disorder Assessment by Molecule Type
  • Generalized Anxiety Disorder by Stage and Molecule Type

 

DelveInsight’s Generalized Anxiety Disorder Report covers around 12+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Generalized Anxiety Disorder product details are provided in the report. Download the Generalized Anxiety Disorder pipeline report to learn more about the emerging Generalized Anxiety Disorder therapies

 

Generalized Anxiety Disorder Pipeline Analysis:

The Generalized Anxiety Disorder pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Generalized Anxiety Disorder with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Generalized Anxiety Disorder Treatment.
  • Generalized Anxiety Disorder key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Generalized Anxiety Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Generalized Anxiety Disorder market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Generalized Anxiety Disorder drugs and therapies

 

Generalized Anxiety Disorder Pipeline Market Drivers

  • Increasing Predominance of Generalized Anxiety Disorder, soaring Applications of Cognitive Behavioral Therapy for GAD, increased Focus on Disease Management are some of the important factors that are fueling the Generalized Anxiety Disorder Market.

 

Generalized Anxiety Disorder Pipeline Market Barriers

  •  However, poor diagnosis, adverse effects of the drugs and other factors are creating obstacles in the Generalized Anxiety Disorder Market growth.

 

Scope of Generalized Anxiety Disorder Pipeline Drug Insight    

  • Coverage: Global
  • Key Generalized Anxiety Disorder Companies: OWP Pharmaceuticals, Mind Medicine, Inc, Luye Pharma Group, ChemRar Research and Development Institute, LLC, and others
  • Key Generalized Anxiety Disorder Therapies: Duloxetine oral suspension, MM-120, LY03005, CD-008-0045, and others
  • Generalized Anxiety Disorder Therapeutic Assessment: Generalized Anxiety Disorder current marketed and Generalized Anxiety Disorder emerging therapies
  • Generalized Anxiety Disorder Market Dynamics: Generalized Anxiety Disorder market drivers and Generalized Anxiety Disorder market barriers 

 

Request for Sample PDF Report for Generalized Anxiety Disorder Pipeline Assessment and clinical trials

 

Table of Contents

1. Generalized Anxiety Disorder Report Introduction

2. Generalized Anxiety Disorder Executive Summary

3. Generalized Anxiety Disorder Overview

4. Generalized Anxiety Disorder- Analytical Perspective In-depth Commercial Assessment

5. Generalized Anxiety Disorder Pipeline Therapeutics

6. Generalized Anxiety Disorder Late Stage Products (Phase II/III)

7. Generalized Anxiety Disorder Mid Stage Products (Phase II)

8. Generalized Anxiety Disorder Early Stage Products (Phase I)

9. Generalized Anxiety Disorder Preclinical Stage Products

10. Generalized Anxiety Disorder Therapeutics Assessment

11. Generalized Anxiety Disorder Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Generalized Anxiety Disorder Key Companies

14. Generalized Anxiety Disorder Key Products

15. Generalized Anxiety Disorder Unmet Needs

16 . Generalized Anxiety Disorder Market Drivers and Barriers

17. Generalized Anxiety Disorder Future Perspectives and Conclusion

18. Generalized Anxiety Disorder Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Generalized Anxiety Disorder Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies involved by DelveInsight | OWP Pharmaceuticals, Mind Medicine, Inc, Luye Pharma

Diabetic Retinopathy Pipeline Analysis, 2024 Updates | Latest FDA, EMA, and PMDA Approvals | Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Diabetic Retinopathy pipeline constitutes 50+ key companies continuously working towards developing 55+ Diabetic Retinopathy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Diabetic Retinopathy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Diabetic Retinopathy Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Diabetic Retinopathy Market.

 

Some of the key takeaways from the Diabetic Retinopathy Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Diabetic Retinopathy treatment therapies with a considerable amount of success over the years. 
  • Diabetic Retinopathy companies working in the treatment market are Palatin Technologies, Avirmax Biopharma, Ocular Therapeutix, Inc., MingSight Pharmaceuticals, Inc, OcuTerra Therapeutics, Inc., RemeGen Co., Ltd, Kodiak Sciences Inc., and others, are developing therapies for the Diabetic Retinopathy treatment 
  • Emerging Diabetic Retinopathy therapies in the different phases of clinical trials are- PL8177, ABI-110, OTX-TKI, MS-553, OTT166, RC28-E injection, KSI-301, and others are expected to have a significant impact on the Diabetic Retinopathy market in the coming years.   
  • In May 2023, Oculic Holding AG unveiled favorable initial outcomes from Stage 1 of the Phase III DIAMOND trial concerning OCS-01 eye drops in diabetic macular edema (DME). The trial’s Stage 1 successfully confirmed the intended dosing regimen’s efficacy for OCS-01 in treating diabetic macular edema, achieving substantial statistical significance as per the company’s statement.
  • In April 2023, Palatin Technologies announced the publication of a manuscript titled “Stimulating the Melanocortin System in Uveitis and Diabetes Preserves the Structure and Anti-Inflammatory Activity of the Retina” in The International Journal of Molecular Sciences. The manuscript, authored by Tat Fong Ng and Andrew W. Taylor from the Department of Ophthalmology at Boston University Chobanian and Avedisian School of Medicine in Massachusetts, summarizes findings on PL8331’s effects in experimental autoimmune uveoretinitis (EAU) and diabetic retinopathy (DR) in mouse models of retinal disease. The study received funding support from Palatin, the National Institute of Health (NIH), and the Massachusetts Lions Eye Research Foundation.
  • In February 2023, Ocugen revealed the submission of an Investigational New Drug application (IND) to the US Food and Drug Administration (FDA) for the commencement of a Phase 1 clinical trial evaluating OCU200. This fusion protein, showcasing a unique mechanism of action (MOA), aims to address diabetic macular edema (DME). The accomplishment of this regulatory milestone fulfills Ocugen’s commitment to file the OCU200 IND within the initial quarter of 2023.
  • In January 2023, Ocuphire Pharma disclosed the top-line findings of its ZETA-1 Phase II trial, assessing oral APX3330 for diabetic retinopathy (DR) treatment. The trial demonstrated promising safety and tolerability of oral APX3330, hinting at its potential as a non-invasive option for safeguarding vision in both eyes among patients with DR.
  • In May 2022, EyePoint Pharmaceuticals disclosed the licensing agreement of EYP-1901 to Betta Pharmaceuticals for development and commercialization in China, Hong Kong, Macau, and Taiwan. While retaining all rights for EYP-1901 globally, EyePoint broadens its exclusive rights concerning the local delivery of vorolanib. This expansion encompasses the treatment of various ophthalmic diseases, encompassing diabetic macular edema (DME).

 

Diabetic Retinopathy Overview

One eye-related consequence of diabetes is diabetic retinopathy. Damage to the blood vessels in the retina, the light-sensitive tissue in the back of the eye, is the root cause of it. Diabetic retinopathy may initially only produce minor vision impairment or no symptoms at all. But blindness may result from it. Any person with type 1 or type 2 diabetes has the potential to acquire the illness.

 

Get a Free Sample PDF Report to know more about Diabetic Retinopathy Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/diabetic-retinopathy-pipeline-insight

 

Emerging Diabetic Retinopathy Drugs Under Different Phases of Clinical Development Include:

  • PL8177: Palatin Technologies
  • ABI-110: Avirmax Biopharma
  • OTX-TKI: Ocular Therapeutix, Inc.
  • MS-553: MingSight Pharmaceuticals, Inc
  • OTT166: OcuTerra Therapeutics, Inc.
  • RC28-E injection: RemeGen Co., Ltd.
  • KSI-301: Kodiak Sciences Inc

 

Diabetic Retinopathy Route of Administration

Diabetic Retinopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical

 

Diabetic Retinopathy Molecule Type

Diabetic Retinopathy Products have been categorized under various Molecule types, such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Diabetic Retinopathy Pipeline Therapeutics Assessment

  • Diabetic Retinopathy Assessment by Product Type
  • Diabetic Retinopathy By Stage and Product Type
  • Diabetic Retinopathy Assessment by Route of Administration
  • Diabetic Retinopathy By Stage and Route of Administration
  • Diabetic Retinopathy Assessment by Molecule Type
  • Diabetic Retinopathy by Stage and Molecule Type

 

DelveInsight’s Diabetic Retinopathy Report covers around 55+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Diabetic Retinopathy product details are provided in the report. Download the Diabetic Retinopathy pipeline report to learn more about the emerging Diabetic Retinopathy therapies

 

Some of the key companies in the Diabetic Retinopathy Therapeutics Market include:

Key companies developing therapies for Diabetic Retinopathy are – Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, Palatin Technologies, Valo Health, EyePoint Pharmaceuticals, Kubota Vision, MingSight Pharmaceuticals, Oxurion, Aerie Pharmaceuticals, AsclepiX Therapeutics, Ocugen, Ashvattha Therapeutics, Stealth BioTherapeutics, and others.

 

Diabetic Retinopathy Pipeline Analysis:

The Diabetic Retinopathy pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Diabetic Retinopathy with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetic Retinopathy Treatment.
  • Diabetic Retinopathy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Diabetic Retinopathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetic Retinopathy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Diabetic Retinopathy drugs and therapies

 

Diabetic Retinopathy Pipeline Market Drivers

  • High healthcare Expenditure, increase in patient awareness about diabetes, presence of well-established healthcare infrastructure and favorable reimbursement framework are some of the important factors that are fueling the Diabetic Retinopathy Market.

 

Diabetic Retinopathy Pipeline Market Barriers

  • However, poor access to care, out-of-pocket expenses, insufficient patient knowledge or awareness of Diabetic Retinopathy and other factors are creating obstacles in the Diabetic Retinopathy Market growth.

 

Scope of Diabetic Retinopathy Pipeline Drug Insight    

  • Coverage: Global
  • Key Diabetic Retinopathy Companies: Palatin Technologies, Avirmax Biopharma, Ocular Therapeutix, Inc., MingSight Pharmaceuticals, Inc, OcuTerra Therapeutics, Inc., RemeGen Co., Ltd, Kodiak Sciences Inc., and others
  • Key Diabetic Retinopathy Therapies: PL8177, ABI-110, OTX-TKI, MS-553, OTT166, RC28-E injection, KSI-301, and others
  • Diabetic Retinopathy Therapeutic Assessment: Diabetic Retinopathy current marketed and Diabetic Retinopathy emerging therapies
  • Diabetic Retinopathy Market Dynamics: Diabetic Retinopathy market drivers and Diabetic Retinopathy market barriers 

 

Request for Sample PDF Report for Diabetic Retinopathy Pipeline Assessment and clinical trials

 

Table of Contents

1. Diabetic Retinopathy Report Introduction

2. Diabetic Retinopathy Executive Summary

3. Diabetic Retinopathy Overview

4. Diabetic Retinopathy- Analytical Perspective In-depth Commercial Assessment

5. Diabetic Retinopathy Pipeline Therapeutics

6. Diabetic Retinopathy Late Stage Products (Phase II/III)

7. Diabetic Retinopathy Mid Stage Products (Phase II)

8. Diabetic Retinopathy Early Stage Products (Phase I)

9. Diabetic Retinopathy Preclinical Stage Products

10. Diabetic Retinopathy Therapeutics Assessment

11. Diabetic Retinopathy Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Diabetic Retinopathy Key Companies

14. Diabetic Retinopathy Key Products

15. Diabetic Retinopathy Unmet Needs

16 . Diabetic Retinopathy Market Drivers and Barriers

17. Diabetic Retinopathy Future Perspectives and Conclusion

18. Diabetic Retinopathy Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Diabetic Retinopathy Pipeline Analysis, 2024 Updates | Latest FDA, EMA, and PMDA Approvals | Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche

NurOwn (MSC-NTF Cells) for Amyotrophic Lateral Sclerosis: Market Size and Share Analysis and Competitive Landscape by DelveInsight | Key Players – Brainstorm-Cell Therapeutics

DelveInsight has released a comprehensive report titled “NurOwn (MSC-NTF Cells) Market Forecast,” offering a thorough examination and predictive insights into the NurOwn (MSC-NTF Cells) market landscape until 2032 across the seven major markets (7MM), encompassing the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

The extensive report offers a thorough examination of the market potential and market share of NurOwn (MSC-NTF Cells) in the therapeutics landscape for Amyotrophic Lateral Sclerosis across the 7MM spanning the years 2019 to 2032. By delving into this analysis, stakeholders gain valuable insights into the evolving landscape of NurOwn (MSC-NTF Cells), encompassing both clinical and commercial dimensions. Key parameters such as the drug’s Mechanism of Action (MOA), Route of Administration (ROA), dosage, and any special designations are meticulously explored, providing a holistic understanding of its profile.

NurOwn (MSC-NTF Cells) Drug Insights

MSC-NTF cells, also known as NurOwn, represent a groundbreaking approach in regenerative medicine. Derived from the patient’s own bone marrow, these mesenchymal stem cells (MSCs) undergo a specialized culture process to stimulate the secretion of potent neurotrophic factors (NTFs). These factors play a vital role in promoting the growth and survival of neurons, offering a promising avenue for treating neurodegenerative conditions.

By harnessing the innate therapeutic properties of MSCs alongside the enhanced secretion of NTFs, MSC-NTF cells provide a unique combination of benefits. Not only do they possess the immunomodulatory abilities inherent to MSCs, but they also offer heightened support for neuronal health and function.

This innovative approach holds great potential for addressing a wide range of neurological disorders, from Parkinson’s disease to amyotrophic lateral sclerosis (ALS). By leveraging the synergistic effects of MSCs and NTFs, MSC-NTF therapy offers new hope for patients seeking effective treatments that target the underlying mechanisms of neurodegeneration.

As research in this field continues to advance, MSC-NTF cells stand out as a promising avenue for improving the lives of those affected by neurological conditions. With ongoing studies and clinical trials, the potential applications of this technology are continually expanding, paving the way for a brighter future in neuroregenerative medicine.

In December 2021, the FDA granted authorization for additional NurOwn dosing within the Expanded Access Program (EAP). Following this authorization, BrainStorm received a recommendation from the FDA to submit an amendment to the EAP protocol, allowing for additional dosing for eligible participants. Initially, under the original EAP protocol, participants who had successfully completed the Phase III NurOwn trial and met specific criteria were eligible to receive three doses of NurOwn. However, with the amended EAP protocol, these qualifying participants now have the opportunity to receive up to three additional doses. The decision to proceed with these additional doses was informed by data collected from the initial EAP treatments, underscoring the importance of evidence-based decision-making in advancing patient care.

Get a detailed overview of the NurOwn (MSC-NTF Cells) drug and stay ahead of the competition by leveraging key insights and evolving trends in the  Amyotrophic Lateral Sclerosis therapeutic market @

https://www.delveinsight.com/sample-request/nurown-msc-ntf-cells-emerging-drug-insight-and-market-forecast

Key Highlights of the NurOwn (MSC-NTF Cells) Market Report

  • The report includes a projected assessment of NurOwn (MSC-NTF Cells) sales for Amyotrophic Lateral Sclerosis up to the year 2032.

  • The report offers in-depth coverage of advanced-stage emerging therapies for the treatment of Amyotrophic Lateral Sclerosis.

  • The report additionally includes both qualitative and quantitative analyses conducted by analysts, along with Key Opinion Leader (KOL) perspectives on NurOwn (MSC-NTF Cells) for Amyotrophic Lateral Sclerosis.

Why NurOwn (MSC-NTF Cells) Market Report?

  • The projected market data for NurOwn (MSC-NTF Cells) in the context of Amyotrophic Lateral Sclerosis will play a crucial role in informing decision-making related to the therapeutic portfolio. It will provide valuable insights into the overall landscape of NurOwn (MSC-NTF Cells), aiding in strategic planning and decision-making processes within the therapeutic domain.

  • A comprehensive market forecast for NurOwn (MSC-NTF Cells) will contribute to a better understanding of how the drug competes with other emerging therapies within the therapeutics landscape. This analysis will provide insights into the drug’s positioning, potential market share, and overall impact on the competitive environment in the therapeutic field.

  • The report additionally offers future market assessments for the NurOwn (MSC-NTF Cells) market in the field of Amyotrophic Lateral Sclerosis across the 7 Major Markets. It encompasses advanced qualitative analyses such as SWOT analysis, insights from expert analysts, a comprehensive overview of market competitors, and a brief analysis of other emerging therapies within the realm of Amyotrophic Lateral Sclerosis. This multifaceted approach ensures a comprehensive understanding of the NurOwn (MSC-NTF Cells) market landscape, combining both quantitative and qualitative perspectives for a well-rounded assessment.

  • Conducting a thorough market forecast for NurOwn (MSC-NTF Cells) will facilitate a detailed analysis of the drug’s clinical trial progress. This examination will encompass a comprehensive assessment of the clinical, regulatory, and commercial aspects, providing valuable insights into the advancements of NurOwn (MSC-NTF Cells). 

Explore key clinical, commercial, and regulatory milestones associated with NurOwn (MSC-NTF Cells) by visiting:

https://www.delveinsight.com/sample-request/nurown-msc-ntf-cells-emerging-drug-insight-and-market-forecast

Table of Contents of the Report

1. Report Introduction

2. NurOwn (MSC-NTF Cells) Overview in Amyotrophic Lateral Sclerosis

3. Competitive Landscape (Key Assessment of the Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies Analysis)

5. NurOwn (MSC-NTF Cells) Market Assessment

6. SWOT Analysis

7. Analysts’ Views

8. Appendix

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

* The final table of contents may be subject to change based on user demand.

Request the Sample PDF to Learn More About the Key Offerings of the NurOwn (MSC-NTF Cells) Market Report:

https://www.delveinsight.com/sample-request/nurown-msc-ntf-cells-emerging-drug-insight-and-market-forecast

 

Other Related Reports By DelveInsight

Amyotrophic Lateral Sclerosis Pipeline Insight

DelveInsight’s “Amyotrophic Lateral Sclerosis Pipeline Insight” report provides comprehensive insights about 90+ companies and 100+ pipeline drugs in the Amyotrophic Lateral Sclerosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products by routes of administration, and molecule types. Furthermore, it further highlights the inactive pipeline products in this space. Some of the key companies in the Amyotrophic Lateral Sclerosis Therapeutics market include Biogen, Sanofi, Novartis Pharmaceuticals, MolecularPartners, Ionis Pharmaceuticals, Denali Therapeutics Inc., AbbVie, Corcept Therapeutics, Woolsey Pharmaceuticals, Ashvattha Therapeutics Inc., NeuroSense Therapeutics Ltd., Retrotope Inc., Clene Nanomedicine, Apellis Pharmaceuticals Inc, and others.

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: NurOwn (MSC-NTF Cells) for Amyotrophic Lateral Sclerosis: Market Size and Share Analysis and Competitive Landscape by DelveInsight | Key Players – Brainstorm-Cell Therapeutics

ANX005 for Huntington’s Disease: Market Size and Share Analysis and Competitive Landscape by DelveInsight | Key Players – Annexon Biosciences

“DelveInsight Business Research LLP”
DelveInsight has released a comprehensive report titled “ANX005 Market Forecast,” offering a thorough examination and predictive insights into the ANX005 market landscape until 2032 across the seven major markets (7MM), encompassing the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

The extensive report offers a thorough examination of the market potential and market share of ANX005 in the therapeutics landscape for Huntington’s Disease across the 7MM spanning the years 2019 to 2032. By delving into this analysis, stakeholders gain valuable insights into the evolving landscape of ANX005, encompassing both clinical and commercial dimensions. Key parameters such as the drug’s Mechanism of Action (MOA), Route of Administration (ROA), dosage, and any special designations are meticulously explored, providing a holistic understanding of its profile.

ANX005 Drug Insights

ANX005, a groundbreaking monoclonal antibody under investigation in clinical stages, aims to address the complex spectrum of antibody-mediated autoimmune and complement-mediated neurodegenerative disorders. This innovative therapeutic approach is specifically tailored for intravenous delivery, strategically targeting the inhibition of C1q and the comprehensive classical complement pathway.

Encouragingly, ANX005 demonstrated a favorable safety profile throughout the trial, with consistent findings aligning with interim results previously disclosed. The collective data from ongoing evaluations indicate that ANX005 has been administered and tolerated satisfactorily in a diverse cohort, encompassing over 170 patients across various indications. These results underscore the potential of ANX005 as a promising candidate in the realm of autoimmune and neurodegenerative disease management.

Get a detailed overview of the ANX005 drug and stay ahead of the competition by leveraging key insights and evolving trends in the  Huntington’s Disease therapeutic market @

https://www.delveinsight.com/sample-request/anx005-huntingtons-disease-emerging-drug-insight-and-market-forecast

ANX005 Market Outlook and Key Assessment

Key Highlights of the ANX005 Market Report

  • The report includes a projected assessment of ANX005 sales for Huntington’s Disease up to the year 2032.
  • The report offers in-depth coverage of advanced-stage emerging therapies for the treatment of Huntington’s Disease.
  • The report additionally includes both qualitative and quantitative analyses conducted by analysts, along with Key Opinion Leader (KOL) perspectives on ANX005 for Huntington’s Disease.

Why ANX005 Market Report?

  • The projected market data for ANX005 in the context of Huntington’s Disease will play a crucial role in informing decision-making related to the therapeutic portfolio. It will provide valuable insights into the overall landscape of ANX005, aiding in strategic planning and decision-making processes within the therapeutic domain.
  • A comprehensive market forecast for ANX005 will contribute to a better understanding of how the drug competes with other emerging therapies within the therapeutics landscape. This analysis will provide insights into the drug’s positioning, potential market share, and overall impact on the competitive environment in the therapeutic field.
  • The report additionally offers future market assessments for the ANX005 market in the field of Huntington’s Disease across the 7 Major Markets. It encompasses advanced qualitative analyses such as SWOT analysis, insights from expert analysts, a comprehensive overview of market competitors, and a brief analysis of other emerging therapies within the realm of Huntington’s Disease. This multifaceted approach ensures a comprehensive understanding of the ANX005 market landscape, combining both quantitative and qualitative perspectives for a well-rounded assessment.
  • Conducting a thorough market forecast for ANX005 will facilitate a detailed analysis of the drug’s clinical trial progress. This examination will encompass a comprehensive assessment of the clinical, regulatory, and commercial aspects, providing valuable insights into the advancements of ANX005. 

Explore key clinical, commercial, and regulatory milestones associated with ANX005 by visiting:

https://www.delveinsight.com/sample-request/anx005-huntingtons-disease-emerging-drug-insight-and-market-forecast

Table of Contents of the Report

1. Report Introduction

2. ANX005 Overview in Huntington’s Disease

3. Competitive Landscape (Key Assessment of the Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies Analysis)

5. ANX005 Market Assessment

6. SWOT Analysis

7. Analysts’ Views

8. Appendix

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

* The final table of contents may be subject to change based on user demand.

Request the Sample PDF to Learn More About the Key Offerings of the ANX005 Market Report:

https://www.delveinsight.com/sample-request/anx005-huntingtons-disease-emerging-drug-insight-and-market-forecast

 

 

Other Related Reports By DelveInsight

Huntington’s Disease Pipeline Insight

DelveInsight’s “Huntington’s Disease Pipeline Insight” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Huntington’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products by routes of administration, and molecule types. Furthermore, it further highlights the inactive pipeline products in this space. Some of the key companies in the Huntington’s Disease Therapeutics market include Prilenia Therapeutics, Ionis Pharmaceuticals, Annexon, Vaccinex, Neurocrine Biosciences, EIP Pharma, SAGE Therapeutics, Celon Pharma, PTC Therapeutics, WaVe Life Sciences, Amsterdam Molecular Therapeutics, Novartis, Retrotope, Hope Biosciences, Stealth BioTherapeutics, Luye Pharma Group, Neurimmune Therapeutics, SOLA Biosciences, and others.

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: ANX005 for Huntington’s Disease: Market Size and Share Analysis and Competitive Landscape by DelveInsight | Key Players – Annexon Biosciences